INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
July 26, 2004
(Use several sheets if necessary)

ATTORNEY DOCKET NO. 1733.1003-012

APPLICATION NO. 10/797,718

FIRST NAMED INVENTOR Howard Bernstein

FILING DATE
March 10, 2004

EXAMINER Monshipo-ni
Not Assigned

CONFIRMATION NO. 4117

GROUP -1615 1656

		U.S	S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.		ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
e.r.	۸۸	4,675,189	06/23/87	Kent, J.S. et al:
	AB	4,962,091	10/09/90	Eppstein, D.A. et al.
	АC	3,523,906	08/11/70	Vrancken, M.N. et al.
	ΑĎ	3,691,090	09/12/72	Kitajima, M. et al.
	ΛE	3,737,337	06/05/73	Schnoring, H. et al.
	AF	3,887,699	06/03/75	Yolles, S.
	ΛG	4,389,330	06/21/83	Tice, T.R. et al.
	ΛН	4,530,840	07/23/85	Tice, T.R. et al.
	ΑI	4,542,025	09/17/85 .	Tice, T.R. et al.
	AJ.	4,835,139	05/30/89	Tice, T.R. et al.
	AK	4,891,225	01/02/90	Langer, R.S. et al.
	ΛΛ2	3,891,570	06/24/75	Fukushima, M. et al.
	AB2	4,391,797	07/05/83	Folkman, M.J. et al.
-	AC2	5,176,907	01/05/93	Leong, K.W.
	AD2	5,122,367	06/16/92	Ron, E. et al.
	AE2	5,145,674	09/08/92	Lanc, G.A. et al.
	AF2	4,711,782	12/08/87	Okada, H. et al.
	AG2	5,126,147	06/30/92	Silvestri, L.J. et al.
	AH2	5,192,741	03/09/93	Orsolini, P. et al.
	AI2	4,732,889	03/22/88	Cynshi, O. et al.
	AJ2	4,879,272	11/07/89	Shimoda, N. et al.
	AK2	4,992,419	02/12/91	Woog, H. et al.
1	ΛΛ3	4,853,218	08/01/89	Yim, Z. et al.
	<b>ЛВ</b> З	4,235,236	11/25/80	Theeuwes, F.
	AC3	4,906,474	03/06/90	Langer, R.S. et al.
e. k ·	AD3	5,019,400	5/28/91	Gombotz, W.R. et al.

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 1733.1003-012 10/797,718			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Howard Bernstein FILING DATE March 10, 2004		2004	
July 26, 2004 (Use several sheets if necessary)	EXAMINER Not Assigned	CONF. 4117	IRMATION NO.	GROUP ## 1656

			U.S	S. PATENT DOCUMENTS	
EXAM INER INI- TIAL	R	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
12. N	e. AE	E3	4,981,696	1/1/91	Loomis, G.L. et al.
	ΑF	F3	4,637,905	1/20/87	Gardner, D.L.
	٨٥	G3	4,897,268	1/30/90	Tice, T.R. et al.
	AF	нз	4,767,628	8/30/88	Hutchinson, F.G.
	AI.	13	3,928,566	12/23/75	Briggs, A.R. et al.
	V1	13	4,166,800	9/4/79	Fong, J.W.
	Ak	кз	4,530,901	7/13/85	Weissmann, C.
	۸/	Λ4	4,871,538	10/02/89	Yim, Z. et al.
	ΑI	В4	B1 4,985,404	04/21/92	Mitchell, J.W.
	AC	C4	4,655,777	04/07/87	Dunn, R.L., et al.
	Λί	D4	5,075,115	12/24/91	Brine, C.J.
	AE	E4	5,344,654	09/06/94	Rueger, D.C., et al.
	AF	F4	4,237,114	12/02/80	Cardarelli, N.F.
	·AC	G4	4,806,524	02/21/89	Kawaguchi, T., et al.
	Λŀ	H4	4,252,791	02/24/81	Grossberg, S.E., et al.
	AI	14	5,441,734	08/15/95	Reichert, P., et al.
	١٨	14	5,413,797	05/09/95	Khan, M.A., et al.
	Ak	K4	5,656,297	08/12/97	Bernstein, et al.
76.5	۸/	A5	5,912,015	06/15/99	Bernstein, et al.
	_				
<u> </u>	-			-	
1					

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	William Programme		APPLICATION NO. 0/797,718		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR FILING DATE Howard Bernstein March 10, 2004		2004		
July 26, 2004 / (Use several sheets if necessary)	EXAMINER Not Assigned	CONF 4117	IRMATION NO.	GROUP 1615 1656	

 		FOREIGN PATENT D	OCUMENTS		
	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
 AL	WO91/12882	05/09/91	Medgenix Group S.A		
 АМ	WO96/07399A1	14/03/96	Takeda Chemical Industries, LTD		
AN	WO93/07861	29/04/93	Board of Regents, The University of Texan System		
 ΑΟ .	WO93/25221	23/12/93	Alkermes Controlled Therapeutics, Inc.		
 AP	WO90/09166	23/08/90	Biosearch, Inc.		
 ΛQ	WO90/13780	15/11/90	Enzytech, Inc.		
 AL2	WO92/11844	23/7/92	Enzytech, Inc.		
AM2	WO95/29664 A1	09/11/95	Alkermes Controlled Therapeutics, Inc.		
AN2	WO94/12158	09/06/94	Alkermes Controlled Therapeutics, Inc.		
 AO2	0633 020 A1	11/01/95	Takeda Chemical Industries, Inc.		
AP2	WO93/17668	16/09/93	Alkermes Controlled Therapeutics, Inc.		
 AQ2	WO94/07469	0/14/94	Dynagen, Inc.		
 AL3	0580 428 A1	01/26/94	Takeda Chemical Industries, Inc.		
 АМ3	0537559 A1	21/04/93	Atrix Laboratories, Inc.		
AN3	0266119 A3	04/05/88	Souther Research Institute & The UAB Research Foundation		
AO3	0330180 A1	30/08/89	Biomaterials Universe, Inc.		
 АРЗ	WO89/03678	05/05/89	Stolle Research & Development Corporation		
 AQ3	WO90/13285	15/11/90	Enzytech, Inc.		
 AL4	0 595 030/A2	05/09/91	Tanabe Seiyaku, Co., LTD.		
 AM4	WO93/02712	18/02/93	Danbiosyst UK Limited		
AN4	w95/11010	27/04/95	Genetech, Inc.		
A04	WO94/19373 A1	01/09/94	Schering Corporation		

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	1 111 101 111 111 111 111 111 111 111 1		APPLICATION NO. 10/797,718		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Howard Bernstein FILING DATE March 10, 2004		2004		
July 26, 2004 (Use several sheets if necessary)	EXAMINER Not Assigned	CONF 4117	IRMATION NO.	GROUP 1615 1696	

		FOREIGN PATENT DO	OCUMENTS		
	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATIO YES NO	
AP4	0 307 097 A2	15/03/89	Takeda Chemical Industries, Inc.		
AQ4	WO91/18927 A1	12/12/91	Schering Corporation		
AL5	0 123 291 A2	31/10/84	Kyowa Hakko Kogyo Co, LTD.		
AM5	0 281 299 A1	07/09/88	Schering Corporation		
AN5	0 251 680 A2	07/01/88	IOLAB, Inc.		
AO5	WO92/19226	12/11/92	Dynagen, Inc.		
AP5	0.052 510 A2	05/26/82	Syntex, Inc.	,	
	·				
	ı				

EXAMINER	DATE CONSIDERED
·	

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1733.1003-012 APPLICATION NO. 10/797,718				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			FILING DATE March 10, 2		
July 26, 2004 (Use several sheets if necessary)	EXAMINER Not Assigned	CONF	RMATION NO.	GROUP 16151656	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
erge.	AR	Pratt, L., et al., "The Effect of Ionic Electrolytes on Hydrolytic Degradation of Blodegradable Polymers: Mechanical and Thermodynamic Properties and Molecular Modeling," J. Polymer Science 31(7):1759-1769 (1993).
e. re	AS	Costantino, H. R., et al., "Solid-Phase Aggregation of Proteins under Pharmaceutically Relevant Conditions," J. of Pharmaceutical Sciences, 83(12):1662-1669 (1994).
16.16.	AT	Costantino, H. R., et al., "Moisture-Induced Aggregation of Lyophilized Insulin," Pharmaceutical Research, 11(1):21-29 (1994).
_	AU _	Costantino, H.R., et al., "Aggregation of a Lyophilized Pharmaceutical Protein, Recombinant Human Albumin: Effect of Moisture and Stabilization by Excipients," Biotechnology, 13:493-496 (1995).
بو.بو	۸۷	Creighton, T.E., "Physical Forces That Determine the Properties of Proteins," In Proteins, Structures and Molecular Principles, (NY: W.H. Freeman and Company), pp. 149-150, 197
_	AW	-Cumingham, B. C., et al., "Dimerization of Human Growth Hormone by Zinc," Science, 253:545-548-(August 1991).
بو. ب <i>ر</i>	AX	Sato, Toyomi, et al., "Porous Biodegradable Microspheres for Controlled Drug Delivery. I. Assessment of Processing Conditions and Solvent Removal Techniques," <i>Pharmaceutical Research</i> , 5(1):21-29 (1988).
H. 14.	AY	Langer, R., "New Methods of Drug Delivery," Science, 249:1527-1533 (September 1990).
re. re	AZ •	Liu, W. R., et al., "Moisture-Induced Aggregation of Lyophilized Proteins in the Solid State," Biotechnology and Bioengineering, 37:177-184 (1991).
re.re	AR2	Lu, W., and Park, T. G., "Protein Release from Poly(lactic-co-glycolic acid) Microspheres: Protein Stability Problems," PDA J. of Pharmaceutical Science & Technology, 49(1):13-19 (Jan-Feb 1995).
૧.૪.	AS2	Cohen, S., et al., "Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres," Pharmaceutical Research, 8(6):713-720 (1991).
ŀē.ĸ.	AT2	Hora, M.S. et al., "Release of Human Serum Albumin from Poly(lactide-co-glycolide) Microspheres," Pharmaceutical Research, 7(11):1190-1194 (1990).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	111101010101		PPLICATION NO. 0/797,718	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Howard Bernstein		FILING DATE March 10, 2004	
July 26, 2004 (Use several sheets if necessary)	EXAMINER Not Assigned	CONF 4117	IRMATION NO.	GROUP 16151656

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
k.k.	AU2	Hageman, M.J., et al., "Preformulation Studies Oriented Toward Sustained Delivery of Recombinant Somatotropins," J. Agric. Food Chem., 40:348-355 (1992).
re.1°.	AV2	Cleland, J. L., et al., "Characterization of Recombinant Human Growth Hormone-PLGA Formulations in Animals," Proceed, Intern. Symp. Control. Rel. Bioact. Mater., 22:143-144 (1995).
_	AW2	Cleland, J. L., et al., "One Month Continuous Release Recombinant Human Growth Hormone-PLGA Formulations," Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22:149-150 (1993).
)	AX2	Mullerad, I., et al., "Delivery of II1 Microspheres to Tumor Macrophages," Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22:512-513 (1995).
١٤.١٤.	AY2	Cleland, J. L., et al., "In Vitro Release of Bioactive Recombinant Human Interferon-y From PLGA Microspheres," Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22:518-519 (1995).
٦٤.١٩.	ÁZ2	Park, T. G., et al., "Importance of In Vitro Experimental Conditions on Protein Release Kinetics, Stability and Polymer Degradation in Protein Encapsulated Poly(D,:-Lactic Acid-Co-Glycolic Acid) Microspheres," J. of Controlled Release, 33:211-222 (1995).
re.re.	AR3	Nagata, S., et al., "Synthesis in E. Coli of a Polypeptide with Human Leukocyte Interferon Activity," Nature, 284:316-320 (March 1980).
	AS3	Rubinstein, M., "The Structure of Human Interferons," Biochimica et Biophysica Acta., 695:5-16 (1982).
ĸr.	АТ3	Sah, H., et al., "The Influence of Biodegradable Microcapsule Formulations on the Controlled Release of a Protein," J. of Controlled Release 30:201-211 (1994).
L	L	

10/23/07	EXAMINER	DATE CONSIDERED
10.700814	19. Plashi	10/23/07